Brian Rini, MD, FASCO

Brian I. Rini, MD, FASCO, is Ingram Professor of Medicine and Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, and co-host of The Uromigos podcast.

Articles by Brian Rini, MD, FASCO

Brian Rini, MD, FASCOVideo Insights | August 1, 2023
Drs. Rini and Plimack discuss the "negative" findings from CONTACT-03.
View More
Brian Rini, MD, FASCOVideo Insights | August 1, 2023
Drs. Rini and Plimack discuss "impressive" non-clear cell RCC data.
Brian Rini, MD, FASCOVideo Insights | July 31, 2023
Drs. Rini and Plimack discuss the CLEAR and KEYNOTE-426 RCC updates.
Brian Rini, MD, FASCORoundtable | July 5, 2023
The panel provides their concluding thoughts on the frontline and refractory RCC treatment landscape.
Brian Rini, MD, FASCORoundtable | July 5, 2023
The panel discusses treatment options in the refractory RCC setting.
Brian Rini, MD, FASCORoundtable | June 28, 2023
The panel discusses what is most exciting to them in the frontline RCC field.
Brian Rini, MD, FASCORoundtable | June 28, 2023
The panel discusses toxicity management and use of precision medicine.
Brian Rini, MD, FASCORoundtable | June 28, 2023
The panelists debate the use of IO/IO versus IO/TKI regimens for frontline RCC therapy.
Brian Rini, MD, FASCORoundtable | June 22, 2023
Dr. Rini describes the CLEAR and KEYNOTE-426 studies presented at ASCO 2023.
Brian Rini, MD, FASCORoundtable | June 12, 2023
The panel discusses the approach to frontline treatment selection for patients with RCC.
Brian Rini, MD, FASCOASCO 2023 | June 5, 2023
Drs. Rini and Wallis discuss the results of a late-breaking abstract on KEYNOTE-426, which now has long-term survival data.
Brian Rini, MD, FASCOVideo Insights | March 16, 2023
In the final segment of a debate series, Brian Rini, MD, and Monty Pal, MD, debate RCC adjuvant therapeutic options.
Brian Rini, MD, FASCORoundtable | March 15, 2023
The panel shares interesting clinical trial data in development, including CONTACT-03, TiNivo-2, and more.
Brian Rini, MD, FASCORoundtable | March 15, 2023
The panel discusses triplet combinations in development for RCC.
Brian Rini, MD, FASCORoundtable | March 15, 2023
The panel discusses the disappointing results of the COSMIC-313 trial.
Brian Rini, MD, FASCOVideo Insights | March 15, 2023
In the second segment of a debate series, Drs. Rini and Pal address kidney cancer clinical trials of interest.
Brian Rini, MD, FASCORoundtable | March 14, 2023
The panel discusses treatment-related toxicities and when to consider stopping treatment.
Brian Rini, MD, FASCOVideo Insights | March 14, 2023
In a debate series between Brian Rini, MD, and Monty Pal, MD, they discuss frontline RCC treatment options.
Brian Rini, MD, FASCORenal Cell Carcinoma | March 10, 2023
The panel compares three treatment regimens.
Brian Rini, MD, FASCORoundtable | March 10, 2023
The panel discusses the CheckMate 8Y8 clinical trial.